Sp1283
RETHINK THE CYCLE: CONSIDER ENTYVIO
Date
May 8, 2023
Society: DDW
An interactive case study discussing a hypothetical patient. This case will cover patient presentation, biomarker and imaging findings, treatment options, follow-up, and a review of ENTYVIO efficacy and safety data. Sponsored by Takeda Pharmaceuticals U.S.A., Inc.
An interactive case study discussing a hypothetical patient. This case will cover patient presentation, biomarker and imaging findings, treatment options, follow-up, and a review of ENTYVIO efficacy and safety data. Sponsored by Takeda Pharmaceuticals U.S.A., Inc.
Presenter
Tracks
Related Products
TOFACITINIB FOR HOSPITALIZED ACUTE SEVERE ULCERATIVE COLITIS - THE TRIUMPH STUDY
Tofacitinib is a rapidly acting Janus kinase (JAK) inhibitor with several case series reporting effectiveness in patients with acute severe ulcerative colitis (ASUC). However, there remains a paucity of prospective data evaluating its efficacy and rapidity of onset in ASUC…
REAL-WORLD CLINICAL EFFECTIVENESS AND SAFETY OF VEDOLIZUMAB AND USTEKINUMAB IN BIOLOGIC-NAÏVE PATIENTS WITH CROHN’S DISEASE: RESULTS FROM THE EVOLVE EXPANSION STUDY
BACKGROUND: Prevention of postoperative recurrence (POR) in Crohn’s disease (CD) after ileo-colonic (IC) resection is still a highly debated topic. Prophylactic immunosuppression after surgery is currently recommended in presence of at least one clinical risk factor (RF)…
DEVELOPMENT AND VALIDATION OF A NOVEL COMPOSITE INDEX FOR THE ASSESSMENT OF ENDOSCOPIC AND HISTOLOGIC DISEASE ACTIVITY IN POUCHITIS: THE ATLANTIC POUCHITIS INDEX
BACKGROUND: Anti-granulocyte macrophage-colony stimulating factor autoantibodies (anti-GM-CSF) have been associated with development of Crohn’s disease (CD) and complications at time of diagnosis. There are limited data on anti-GM-CSF as a prognostic biomarker in CD…
SERUM METABOLOMICS IDENTIFIES DYSREGULATED PATHWAYS AND POTENTIAL METABOLIC BIOMARKERS INVOLVED IN DEVELOPMENT OF CROHN’S DISEASE
Aconitate decarboxylase 1 (ACOD1; also known as IRG-1) is the ubiquitous source of the metabolite itaconate, which dampens inflammasome activation by preventing HIF1α production of IL-1β and prevents TNF production through NRF2 activation…
